EVALUATION OF THE CARDIOTOXIC EFFECTS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHOTREXATE IN PATIENTS WITH HYPERTENSION COMORBID WITH RHEUMATOID ARTHRITIS

Rakhimova M.E; Khalmetova F.I; Jaynakova M.Y

Authors

Rakhimova M.E Author
Khalmetova F.I Author
Jaynakova M.Y Author

Abstract

Hypertension is one of the most prevalent and lethal diseases worldwide, including in our republic. When hypertension occurs in comorbidity with rheumatoid arthritis (RA), the patient's general condition deteriorates significantly. Another factor complicating the clinical situation is the potential cardiotoxic effect of the primary drugs used in the treatment of RA, specifically non-steroidal anti-inflammatory drugs (NSAIDs) and methotrexate. This article analyzes observations and studies conducted by leading global researchers regarding these specific clinical scenarios.

References

1. Ahsan A, Sahu MA. Cardiovascular risk of NSAIDs: A review. Cureus. 2025;17(1):e52341.

2. Akhmedov, K., Abdurakhmanova, N., & Buranova, S. (2023). Features of the clinical course of rheumatoid spice against the background of the influence of xenobiotics. American Journal of Interdisciplinary Research and Development, 12, 142-147.

3. Axmedov, I. A., Xalmetova, F. I., & Zaripov, S. I. (2024). Rematoid artrit kasalligi bo ‘lgan bemorlarda yurak qon-tomir tizimidagi buzulishlarni erta aniqlashda yurak ritmi buzilishlarining o ‘rni.

4. Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs. BMJ. 2024;384:e073125.

5. Buranova, S. (2021). Method of treatment aimed at the dynamics of cartilage oligomer matrix protein (COMP) in patients with osteoarthritis.

6. Dijkshoorn B, Raadsen R, Nurmohamed MT. Cardiovascular disease risk in rheumatoid arthritis: Anno 2022. J Clin Med. 2022;11(7):1810.

7. England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis. BMJ. 2023;380:e072816.

8. GBD 2024 Rheumatoid Arthritis Collaborators. Global prevalence and burden of rheumatoid arthritis in 2024. Ann Rheum Dis. 2024;83:789-798.

9. Hadwen B, Stranges S, Barra L. Risk factors for hypertension in rheumatoid arthritis. Autoimmun Rev. 2021;20(9):102879.

10. Khalmetova, F. I., Akhmedov, K. S., Buranova, S. N., Rakhimova, M. B., Rakhimov, S. S., & Abdurakhimova, L. A. (2023). Immunological Features of Reactive Arthritis of Various Etiologies. Journal of Coastal Life Medicine, 11, 1322-1325.

11. Mangoni AA, Zinellu A, Sotgia S, Carru C, Erre GL, Tommasi S. Methotrexate and cardiovascular prevention. Ther Adv Cardiovasc Dis. 2023;17:175394472311561.

12. Rakhimova, M. B., Akhmedov, K. S., & Turaev, Y. A. (2021). Endothelial dysfunction as a link in the pathogenesis of ankylosing spondylitis against the background of a new coronavirus infection. ACADEMICIA: An International Multidisciplinary Research Journal, 11(3), 2493-2498.

13. Абдурахимов, А. Г., & Халметова, Ф. И. (2023). Нестероидные противовоспалительные препараты у пациентов с деформирующим остеоартрозом и артериальной гипертензией: анализ влияния целекоксиба и мелоксикама на антигипертензивные средства. Оптимизация лечения. Атеросклероз, 19(3), 186-187.

14. Рахимова, М. Б., Ахмедов, Х. С., & Халметова, Ф. И. (2025). ОЦЕНКА ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ.

15. Рахимова, М., Ахмедов, К., Буранова, С., и Турсунова, Л. (2022). Оценка сердечно-сосудистых событий у пациентов с анкилозирующим спондилитом после COVID-19.

16. Шовкатова, М. Н., & Рахимова, М. Б. (2025). ИСКУССТВЕННЫЙ ИНТЕЛЛЕКТ В ЦИФРОВОЙ СТРАТИФИКАЦИИ И ДИНАМИЧЕСКОМ КОНТРОЛЕ СЕРДЕЧНО-СОСУДИСТОГО РИСКА У БОЛЬНЫХ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ И РЕВМАТОИДНЫМ АРТРИТОМ. FARS International Journal of Education, Social Science & Humanities., 13(12), 7-14.